Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$3.19 -1.5%	$1.51	$0.80 ▼ $3.42	$133.12M	-0.98	1.07 million shs	398,797 shs
NGNE Neurogene	$22.72 -0.4%	$19.68	$6.88 ▼ $74.49	$325.32M	1.51	212,549 shs	75,610 shs
OCGN Ocugen	$1.09 -2.7%	$1.01	$0.52 ▼ $1.66	$327.08M	4.18	6.50 million shs	1.49 million shs
UPXI Upexi	$6.11 -4.7%	$8.04	$1.90 ▼ $22.57	$572.81M	-0.58	11.80 million shs	13.18 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	-1.54%	+94.51%	+117.01%	+179.82%	+32.92%
NGNE Neurogene	-0.39%	+1.70%	+34.60%	+47.44%	-46.84%
OCGN Ocugen	-2.68%	+6.86%	+4.81%	+51.56%	-31.88%
UPXI Upexi	-4.68%	-18.32%	+83.48%	-60.61%	-23.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.0674 of 5 stars	3.3	3.0	2.4	1.7	0.0
NGNE Neurogene	3.5663 of 5 stars	4.4	2.0	3.2	2.5	0.6
OCGN Ocugen	1.2242 of 5 stars	3.5	1.0	2.0	0.0	0.0
UPXI Upexi	2.9468 of 5 stars	3.5	1.0	3.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	72.41% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	103.20% Upside
OCGN Ocugen	3.00	Buy	$6.00	450.46% Upside
UPXI Upexi	3.00	Buy	$16.00	161.87% Upside

Current Analyst Ratings Breakdown

Latest ANEB, UPXI, NGNE, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00

(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NGNE Neurogene	$930K	348.37	N/A	N/A	$20.89 per share	1.09
OCGN Ocugen	$4.52M	70.39	N/A	N/A	$0.10 per share	10.90
UPXI Upexi	$26M	21.00	N/A	N/A	$6.24 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/23/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/1/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest ANEB, UPXI, NGNE, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	NGNE Neurogene	-$1.15	N/A	N/A	N/A	N/A	N/A
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	$0.35 million	N/A
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
NGNE Neurogene	N/A	21.03	21.03
OCGN Ocugen	1.74	2.60	2.60
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
NGNE Neurogene	52.37%
OCGN Ocugen	10.27%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
NGNE Neurogene	11.64%
OCGN Ocugen	4.42%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
OCGN Ocugen	80	292.03 million	279.12 million	Optionable
UPXI Upexi	130	89.36 million	25.93 million	Optionable

ANEB, UPXI, NGNE, and OCGN Headlines

Recent News About These Companies

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25 at 7:24 PM | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Purchases 11,000 Shares of Stock

July 25 at 7:24 PM | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) CEO Buys 161,943 Shares of Stock

July 25 at 6:54 PM | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25 at 6:47 AM | insidertrades.com

Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

July 25 at 4:21 AM | manilatimes.netM

Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

July 21, 2025 | globenewswire.com

Upexi Shares Slump After $50M Private Placement Offering Closes

July 17, 2025 | marketwatch.com

Upexi call volume above normal and directionally bullish

July 17, 2025 | msn.com

Upexi Shares Jump After Securing $150 Million in Convertible Notes Backed by Solana

July 17, 2025 | msn.com

Upexi Announces Closing of $50 Million Private Placement Equity Offering

July 15, 2025 | manilatimes.netM

Upexi Announces Closing of $50 Million Private Placement Equity Offering

July 15, 2025 | globenewswire.com

Upexi, Inc. Announces Pricing of $200 Million Concurrent Private ...

July 13, 2025 | seekingalpha.com

Upexi raises $200M to boost its Solana treasury

July 12, 2025 | msn.com

Upexi prices $200M private placement of common stock and convertible notes

July 11, 2025 | msn.com

SOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury Strategy

July 11, 2025 | finance.yahoo.com

Upexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq Rules

July 11, 2025 | globenewswire.com

Upexi (NASDAQ:UPXI) Trading 26.7% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Upexi, Inc. (UPXI) Latest Stock News & Headlines - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | Morningstar

June 27, 2025 | morningstar.comM

Upexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - Nasdaq

June 27, 2025 | nasdaq.com

Solana-Focused Upexi to Tokenize Shares; Added 56K SOL to Holdings

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB, UPXI, NGNE, and OCGN Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$3.19 -0.05 (-1.54%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$3.20 +0.00 (+0.16%)

As of 07/25/2025 07:56 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Neurogene NASDAQ:NGNE

$22.72 -0.09 (-0.39%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$22.82 +0.10 (+0.44%)

As of 07/25/2025 04:11 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Ocugen NASDAQ:OCGN

$1.09 -0.03 (-2.68%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$1.09 0.00 (0.00%)

As of 07/25/2025 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Upexi NASDAQ:UPXI

$6.11 -0.30 (-4.68%)

Closing price 07/25/2025 04:00 PM Eastern

Extended Trading

$6.29 +0.18 (+2.95%)

As of 07/25/2025 07:59 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time